HCV Treatment:  The current treatment for hepatitis C, including outcomes, side effects and treatment of various HCV populations

 

·        Consensus Interferon

o       168. The DIRECT Trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): Treatment of Non-Responders to Previous Pegylated Interferon plus Ribavirin: Sustained Virologic Response Data

o       355. Hepatitis C Virus (HCV) Treatment Outcomes with Consensus Interferon with or without Ribavirin in Peginterferon/Ribavirin Non-responders/Relapsers: Results from National Clinical Practice Settings (updated November 19, 2007)

o       541. Consensus Interferon Therapy for Hepatitis C Recurrence After Pegylated Intereferon Failure Post Liver Transplant (updated November 9, 2007)

o       1306. Treatment of Peginterferon/Ribavirin Nonresponders with daily Dosing of Consensus Interferon and Ribavirin - Preliminary Results of the German Consensus Interferon Multicenter Study

o       1317. Treatment of Hepatitis C Patients with Child A and B cirrhosis with Consensus Interferon and Ribavirin in a Low Ascending Dosing Regimen Leads to Significant Viral Elimination Rates

o       1319. Analysis of Relapse Rates in Pegylated Interferon and Ribavirin Non-Responders Treated With Daily Consensus Interferon and Ribavirin

o       1323. Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 or 3

o       1324. Daily consensus interferon versus peg-interferon alfa2b with weight based ribavirin in treatment-naive patients with chronic hepatitis C genotype 1

o       1332. U.S. multicenter pilot study of daily consensus interferon (infergen) plus ribavirin for “difficult-to-treat” HCV genotype 1 patients: tolerance and on-therapy virologic response. (updated November 6, 2007)

 

·        Disease Progression

o       243. Positive Impact of Antiviral Therapy on the Long Term Outcome of Chronic Hepatitis C Patients with Cirrhosis (updated November 3, 2007)

o       244. Long-term prognosis of elderly patients with hepatitis C virus-related chronic liver disease --- A cohort study of 2,379 Japanese patients

o       273. Impact of antiviral therapy and response to treatment on long-term outcome of chronic hepatitis C (CHC):a propensity score analysis in a population-based cohort of 1159 patients

o       319. Hepatocellular carcinoma in long-term sustained virologic responders to antiviral treatment for chronic hepatitis C (updated November 3, 2007)

o       338. Bone mineral density and metabolism in non-cirrhotic patients with chronic hepatitis C before and after antiviral therapy with pegylated interferon α and ribavirin: a prospective controlled study (updated November 3, 2007)

 

·        Extrahepatic Manifestations

o       236. Rituximab combined with Peg-Interferon-Ribavirin in refractory HCV-associated cryoglobulinemia vasculitis. (updated November 3, 2007)

o       331. Hepatitis C Associated Systemic Cryoglobulinemia: Successful Treatment With Plasma Exchange

 

·        General

o       176. Pre-treatment PD-1 expression on HCV-specific CTLs predicts early and long-term response to combination therapy in African Americans but not Caucasian Americans

o       179. Importance of a Minimal Residual Viremia for the Relapse Prediction in HCV Type 1 Patients Receiving Standard or Individualized Treatment Duration

o       263. Morphological analysis and assessment of HCV-RNA and ribavirin concentration in seminal fluid of chronic hepatitis C patients undergoing antiviral combination therapy (updated November 3, 2007)

o       265. Improved Response Rates with Treatment Extension to 72 weeks in Slow Responders to Peginterferon and Weight-Based Ribavirin in Chronic Hepatitis C Virus (HCV) Infection (updated November 3, 2007)

o       268. Treatment of recently acquired hepatitis C infection in injecting drug users: Preliminary results from The Australian Trial in Acute Hepatitis C (ATAHC) (updated November 9, 2007)

o       269. Short-term prolongation of peginterferon plus ribavirin combination therapy is a safe and effective treatment strategy for genotype 1b chronic hepatitis C patients

o       275. Insulin Resistance (IR) defined by the homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during Pegylated-Interferon therapy for Chronic Hepatitis C (updated November 3, 2007)

o       277. Does prolonged therapy in HCV-genotype 3 patients with high viral load improve sustained viral response rates?

o       281. Real-life Rates of Treatment Completion for HCV(updated November 9, 2007)

o       291. Bezafibrate treatment for chronic hepatitis C after failure of previous combination therapy with Interferon and Ribavirin (updated November 3, 2007)

o       293. Early reduction of Ribavirin leads to retardation of viral clearance and affects SVR (updated November 3, 2007)

o       299. Evaluation of a multidisciplinary support program in hepatitis C treatment (updated November 3, 2007)

o       315. Hepatitis C treatment outcomes in the Rhode Island Department of Corrections (updated November 3, 2007)

o       324. Prevalence of Bipolar Affective Disorder in Patients with a Positive Depression Screen at the Initiation of Interferon Therapy for Chronic Hepatitis C

o       347. Description of Patients with Viral Breakthrough During PEG IFN and Ribavirin Treatment for Chronic HCV Genotype 1 (updated November 3, 2007)

o       348. Extending antiviral treatment for 12 months after HCV-RNA clearance is associated with a high response rate in difficult-to-treat HCV patients (updated November 3, 2007)

o       1314. Treatment of Alcoholic HCV Patients with Acetaminophen 4 g/Day for 5 Days Does Not Affect Hepatic Tests Compared to Placebo (updated November 9, 2007)

o       1320. The Effect of Complete and Partial Response at Week 12 on Sustained Virologic Response: Results from Controlled Trials in Naïve HCV Genotype 1 Patients Treated With Pegylated Interferon and Ribavirin

o       1321. Comparison of standard vs extended pegylated interferon plus ribavirin treatment according to the time of HCV RNA negative in patients with genotype 1 and high viral load.

o       1326. A 52 week multi-centre, randomized, double-blind placebo-controlled trial evaluating the efficacy and safety of glycyrrhizin in patients with chronic hepatitis C not responding to IFNα or PEG-IFN plus ribavirin therapy (updated November 9, 2007)

o       1361. Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis c infection: results of a controlled follow-up study

o       1384. SVRScore: a Novel and Highly Predictive Score for SVR Prediction in Chronic Hepatitis C Genotype 1 Infected Patients (updated November 9, 2007)

 

·        Herbal Treatments

o       1383. Botanical Medicines for Hepatitis C

 

·        HIV/HCV Coinfection

o       259. Five years assessment of the risk of end-stage liver disease in HIV/HCV co-infected patients treated for a chronic HCV infection

o       264. Fosamprenavir in HAART schedule induces a rapid virological and biochemical response to HCV coupled to Th1 boosting in HIV/HCV coinfected patients  (updated November 3, 2007)

o       342. Negative Impact of Abacavir on Response to pegIFN plus RBV in HIV/HCV Coinfected Patients (updated November 4, 2007)

o       343. Sustained Virologic Response (SVR) To Peg-Interferon Plus Ribavirin In Genotype-4 HCV-HIV Coinfected Patients (updated November 4, 2007)

o       345. Re-treatment with Pegylated Interferon plus Weight-Adjusted Ribavirin in HIV+ Patients with Chronic Hepatitis C: The PILOT-NR Study (updated November 4, 2007)

 

·        IDU

o       295. Treatment Uptake and Outcomes Among Current and Former Injection Drug Users (IDUs) Receiving Directly Observed Therapy Within a Multidisciplinary Group Model for the Treatment of Hepatitis C Virus (HCV) Infection (updated November 4, 2007)

o       296. Infrequent Hepatitis C Virus (HCV) Re-infection after Sustained Virological Response (SVR) Among Current and Former Injection Drug Users (IDUs) Having Received Treatment for HCV Infection (updated November 4, 2007)

o       346. Feasibility of combination therapy for chronic hepatitis C in IVDU in the framework of an heroin detoxification protocol (updated November 4, 2007)

 

·        Liver Transplantation

o       239. Preemptive Treatment of HCV After Liver Transplantation Is Unjustified Except for Genotype 3a.

 

·        Methadone

o       253. Opioid maintenance therapy is not associated with treatment failure to hepatitis C therapy in a large German multicentre cohort (updated November 3, 2007)

 

·        Pegasys

o       LB1. Prolonged Antiviral Therapy With Peginterferon to Prevent Complications of Advanced Liver Disease Associated With Hepatitis C: Results of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial

o       LB4. Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study

o       25. Prophylactic Peginterferon Alfa-2a/Ribavirin vs No Prophylaxis Following Orthotopic Liver Transplantation (OLT) for Hepatitis C: 24-Week Virologic and Safety Responses (updated November 19, 2007)

o       54. Rapid and early virological response rates are increased with 12 week 360 µg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study

o       164.  HCV Patients with Genotype 2 or 3 Who Do Not Achieve a Rapid Virologic Response (RVR) with Peginterferon alfa-2a (40KD)(PEGASYS®) and Ribavirin (COPEGUS®) Are Not Easy to Treat: An analysis of non-RVR patients from the ACCELERATE study

o       180. Sustained Virologic Response rates with albinterferon alfa-2b plus ribavirin treatment in IFN-naïve, chronic hepatitis C genotype 1 patients

o       233. An Open Label, Comparative, Multicenter Study Of Peginterferon Alfa-2a Plus Ribavirin in The Treatment Of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection Versus Those With Chronic Hepatitis C (updated November 12, 2007)

o       234. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alfa-2a and ribavirin (updated November 3, 2007)

o       235. Randomized, double-blind, placebo-controlled trial of Peginterferon alfa-2a (40kD) and ribavirin with and without 400 mg amantadine-sulphate for 48 weeks in treatment naïve HCV genotype 1-infected patients

o       237. Twice vs Once Weekly Dosing of Peginterferon Alfa 2a in Chronic HCV Genotype 1 Infection: Analysis of Early Viral Kinetics (updated November 3, 2007)

o       245. Efficacy and Safety of Escitalopram for the Prevention of Depressive Episodes Induced by Peg-Interferon Alpha2a and Ribavirin in Chronic Hepatitis C Patients. A Double-Blind, Randomized, Placebo-Controlled Trial. (updated November 3, 2007)

o       251. Response to high ribavirin dose in combination with peg-INF alfa-2a for treatment of HCV genotype 1 previous non-responders (updated November 3, 2007)

o       271. Predictors of Response to Pegylated Interferon-α2A and Ribavirin in a Cohort of Patients Infected with the Same Strain of HCV: The O’Brien Project

o       276. Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) (PEG) and Ribavirin (RBV) in naïve patients with HIV-HCV co-infection in the real-life setting in Germany (updated November 4, 2007)

o       285. Efficacy of peginterferon alfa-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: results of the French Hepatys study

o       310. Effects of systematic nurse-provided therapeutic education on adherence and efficiency of PEG-Interferon-a2a(Pegasys®)-ribavirin treatment in chronic hepatitis C (Pegobs Protocol)

o       322. Low dose peginterferon alfa-2a and ribavirin for chronic hepatitis C, genotype 2 & 3: viral kinetics, efficacy and safety

o       321. High rates of sustained virological response (SVR) in patients >50 years infected with HCV genotype 1 with positive prognostic factors treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) (updated November 4, 2007)

o       327. Comparison of efficacy of treatment with peginterferon alfa-2a plus ribavirin vs peginterferon alfa-2b plus ribavirin among patients chronically infected with non 2/3 HCV genotypes with low and high pretreatment viral load

o       328. PEG Interferon ALFA-2A Monotherapy in Dialysis Patients Infected with Hepatitis C Virus (updated November 3, 2007)

o       334. Eight-week oral administration of meloxicam, a COX-II specific non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon alfa-2a in the treatment of chronic hepatitis C

o       337. PEG-IFN alfa-2A plus Ribavirin is Superior Compared to High Dose Consensus Interferon (CIFN) and Ribavirin in the Treatment of Patients with Chronic Hepatitis C (updated November 4, 2007)

o       352. The depression induced by peginterferon alfa-2a and ribavirin in the treatment of chronic hepatitis C is under-diagnosed by the clinician

o       1301. Response-guided therapy in a prospective trial of peginterferon alfa-2a (40KD)/ribavirin treatment in patients with genotypes 1 or 4 (updated November 3, 2007)

o       1305. Association of Pre-Treatment and On-Treatment Factors with Rapid Virologic Response in HCV Genotype 1 Infected Patients Treated with PegIFNα-2a/RBV

o       1309. Final Results of Patients Receiving Peg-Interferon-Alfa-2a (Peg-IFN) and Ribavirin (RBV) After a 14-Day Study of the Hepatitis C Protease Inhibitor Telaprevir (VX-950), With Peg-IFN

o       1308. Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®)

o       1310. Retreatment of HCV Genotype 1 Relapse Patients to Peginterferon/Ribavirin Therapy with an extended Treatment Regimen of 72 weeks with Consensus Interferon/Ribavirin versus Peginterferon alpha/Ribavirin

o       1316. High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 wks with peginterferon alfa-2a (PEGASYS®) plus ribavirin (COPEGUS®): Prospective, randomized, controlled study comparing 24 and 48 weeks of treatment

o       1329. Viral Kinetics Of HCV Genotype 4 During Pegylated Interferon Alpha 2a –Ribavirin Therapy

o       1303. Peginterferon ALFA-2A and Ribavirin for 12 or 24 Weeks in Patients With HCV Genotype 2/3: The Nordynamic Trial

o       1327. Comparison of peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the CLEO trial (updated November 6, 2007)

 

·        PEG-Intron

o       51. Sustained Virologic Response with albinterferon alfa-2b/ribavirin treatment in prior interferon therapy non-responders

o       238. Sustained Virological Response Is Associated with Eradication of Hepatitis C Virus and Decrease in anti-HCV Titer in Patients Treated for Chronic Hepatitis C with Interferon alpha 2b or Pegylated Interferon alpha-2b+ribavirin.

o       246. Response to Peginterferon alfa-2b + Ribavirin Combination Therapy in Genotype 2 and 3 Patients With Poor Baseline Prognostic Factors: Results of the Canadian POWeR Program (updated November 12, 2007)

o       254. Final Results of the Canadian POWeR (Peginterferon alfa-2b Prospective Optimal Weight-based Dosing Response) Program. Sustained Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b + Ribavirin in a Large, Mixed Community and Academic Observational Study (updated November 3, 2007)

o       261. Relapse rates among HCV Genotype 1 early virological responders in a retrospective community-based cohort of patients treated with PEGETRON® in British Columbia, Canada (updated November 3, 2007)

o       262. Viral and STAT kinetics in patients with chronic hepatitis C treated with pegylated interferon a-2b plus ribavirin (updated November 3, 2007)

o       272. Time to HCV RNA Negativation in Hepatitis C Virus (HCV) Type 1-Infection During PEG-Interferon-alpha-2B plus Ribavirin Therapy: Differences in Relation to the Assay Sensitivity (Indiv-1 Study Group) (updated November 3, 2007)

o       279. Treatment of Hemodialysis (HD) Patients With Chronic Hepatitis C (CHC) Using an Escalating Dose Regimen of Pegylated Interferon (PEG-IFN) alfa-2b

o       297. Pegylated Interferon alfa-2b plus Ribavirin reduces insulin resistance and improves glucose metabolism in patients with chronic hepatitis C

o       302. Consistency of Sustained Virologic Response (SVR) Across Weight Categories: Results From the Canadian POWeR (Peginterferon alfa-2b Prospective Optimal Weight-based Dosing Response) Program (updated November 12, 2007)

o       309. Impact of reducing peginterferon alfa-2b and ribavirin on early viral response in genotype 1 infected patients with chronic hepatitis C

o       312. Viral kinetics can quickly predict sustained virological response in HCV patients with normal ALT treated with pegylated ifn α2b and ribavirin: a prospective study

o       318. The level of pretreatment HCV core antigen is a new and useful predictor for the efficacy of peginterferon alpha-2b and ribavirin in patients with chronic hepatitis C

o       325. Patient education improves adherence to peginterferon α-2b and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life study (CHEOBS Study) (updated November 12, 2007)

o       326. Peginterferon alfa-2b and ribavirin treatment of patients with chronic hepatitis C and normal versus elevated aminotransferase levels – final results of a prospective open trial (updated November 3, 2007)

o       336. Treatment and outcome of genotype 4 chronic hepatitis C patients with PegInterferon alfa 2b and Ribavirin in the clinical setting in Germany (updated November 3, 2007)

o       353. Combination therapy with pegylated interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal aminotransferase levels (updated November 4, 2007)

o       1311. Long-term Low Dose Treatment with Pegylated Interferon alpha 2b leads to a significant Reduction in Fibrosis and Inflammatory Score in Chronic Hepatitis C Nonresponder Patients with Fibrosis or Cirrhosis (updated November 3, 2007)

o       1315. Favorable quality of life (QoL) with albinterferon alfa-2b plus ribavirin in genotype 1, IFN-naïve, chronic hepatitis C (CHC) patients

o       1322. Tolerability of Low-Dose Peginterferon alfa-2b in Hepatitis C Patients with Cirrhosis: Results from the CoPilot Trial

 

·        Predictors of Treatment Response

o       249. Pretreatment insulin sensitivity contributes to the treatment response to peginterferon plus ribavirin combination therapy for patients with chronic hepatitis C (updated November 3, 2007)

o       282. Clinical Relevance of Rapid Virological Response (RVR) in Decompensated HCV-Related Cirrhosis Treated with PEG-Interferon and Ribavirin

o       284. Iron Depletion and Response to Interferon in Chronic Hepatitis C (HCV) : A Meta-Analysis (updated November 3, 2007)

o       290. Predictors of Sustained Virological Response to Interferon-based Treatment in Hemodialysis Patients with Chronic Hepatitis C Virus Infection - a Patient Level Meta-analysis

o       298. Whole-body, not only liver, insulin sensitivity is strongly associated with an early and sustained virologic response to peginterferon plus ribavirin treatment in patients with chronic hepatitis C genotype 1b and high viral load

o       301. The Impact Of Steatosis And Steatohepatitis On The Response To Treatment In Patients With Chronic Hepatitis C Infection

o       303. Rapid Virological Response at Week 4 is the Best Predictor of Treatment Outcome in Patients with Chronic Hepatitis C: A Multivariate Analysis (updated November 3, 2007)

o       304. Assessment of Both Virological Response at Week 4 and at Week 12 Optimizes Prediction of Treatment Outcome in Patients with Chronic Hepatitis C Treated with Peginterferon alfa-2B Plus Ribavirin  (updated November 3, 2007)

o       305. Predictability of Response: Positive and Negative Predictive Values of Rapid and Early Virologic Responses to Peginterferon alfa-2b and Ribavirin in the Treatment of Chronic Hepatitis C

o       308. High predictive value of early viral kinetics in peginterferon plus ribavirin combination therapy of genotype 1 infected patients with chronic hepatitis C

o       320. Systemic Factors Associated with Virologic Nonresponse to Peginterferon/Ribavirin Retreatment of Chronic Hepatitis C

o       340. Factors Impacting SVR in HCV Genotype 1 Patients with EVR and Week 24 Negativity (updated November 4, 2007)

o       349. Ultra Rapid Virologic Response Predicts Sustained Virologic Response in HCV Infected Patients with Genotype 3 and High Viral Load: The Get-C Study

o       354. The Role of Steatosis and Diabetes as a Predictor of Treatment Response to Interferon Based Therapies in Latino Americans with Chronic Hepatitis C

 

·        Side Effects

o       258. Assessment of the impact of psychiatric disorders on safety, compliance, and sustained virological response after hepatitis C treatment (CHEOBS)

o       316. The cerebral metabolic and cognitive effects of Pegylated Interferon (PIFN) and hepatitis C viral (HCV) clearance

o       330. GM-CSF May Modulate the Response to Therapeutic IFN-α in Chronic Hepatitis C Virus (HCV) Infection (updated November 4, 2007)

o       351. Incidence and management of psychiatric disturbance in hepatitis C patients treated outside of sponsored research protocols with peginterferon and ribavirin

o       352. The depression induced by peginterferon alfa-2a and ribavirin in the treatment of chronic hepatitis C is under-diagnosed by the clinician (updated November 4, 2007)

 

·        Side Effect Management

o       260. Danazol Increases the Platelets Count in Thrombo-Cytopenic Patients with Chronic Hepatitis C and Liver Cirrhosis Treated With Peg-Interferon Alfa 2a and Ribavirin (updated November 3, 2007)